DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property ...

Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by ...

DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ: NASDAQ:APRE), a biopharmaceutical company with a market capitalization of $21.2 million focused on developing treatments targeting cancer cell ...

宾夕法尼亚州多伊尔斯镇 - 市值2,120万美元的生物制药公司Aprea Therapeutics, Inc. (NASDAQ: APRE)宣布更新其专利组合。该公司专注于开发针对癌细胞脆弱性的治疗方案。根据 InvestingPro 数据显示，公司股票目前交易价格为3.90美元，年初至今上涨18.54%。公司总裁兼首席执行官Oren ...

Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Gilad Oren, the President and CEO of Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired 500 shares of common stock in the company. The purchase, valued at approximately... DOYLESTOWN, Pa. - ...

H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and... Aprea Therapeutics Announces ...

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% ...

Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. Get Aprea Therapeutics alerts: Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its quarterly ...